Tuberculosis in the developing world: Recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis

Current Opinion in Infectious Diseases

Volumn 21, Issue 5, 2008, Pages 454-461

  Grandjean, Louis ^a   Moore, David A J ^b  

^a St Mary's Hospital Campus ^*  (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Diagnosis; Drug resistance; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; BCG VACCINE;

COLORIMETRY; DEVELOPING COUNTRY; DRUG SENSITIVITY; GENOTYPE; HEALTH CARE COST; HUMAN; LABORATORY AUTOMATION; LIQUID CULTURE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; RELIABILITY; REVIEW; SENSITIVITY ANALYSIS; TUBERCULOSIS; TUBERCULOSIS CONTROL; HEALTH; IMMUNOLOGICAL PROCEDURES; MASS SCREENING; METHODOLOGY; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

HUMANS; IMMUNOLOGIC TESTS; MASS SCREENING; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 55249099304     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32830ce783     Document Type: Review

References (105)

1. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006; 6:413-422.
2. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn 2006; 6:423-432.
3. World Health Organisation. Global tuberculosis control 2008: surveillance, planning, financing. 2008. A useful review of the current state of global tuberculosis control.
4. Angeby KA, Hoffner SE, Diwan VK. Should the 'bleach microscopy method' be recommended for improved case detection of tuberculosis? Literature review and key person analysis. Int J Tuberc Lung Dis 2004; 8:806-815.
5. Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:664-674.
6. Anthony RM, Kolk AH, Kuijper S, Klatser PR. Light emitting diodes for auramine O fluorescence microscopic screening of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2006; 10:1060-1062.
7. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:570-581.
8. Levy H, Feldman C, Sacho H, et al. A reevaluation of sputum microscopy and culture in the diagnosis of pulmonary tuberculosis. Chest 1989; 95:1193-1197.
9. Urbanczik R. Present position of microscopy and of culture in diagnostic mycobacteriology. Zentralbl Bakteriol Mikrobiol Hyg [A] 1985; 260:81-87.
10. Hargreaves NJ, Kadzakumanja O, Whitty CJ, et al. 'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. Int J Tuberc Lung Dis 2001; 5:847-854.
11. World Health Organisation. Anti Tuberculosis Drug Resistance in the World 4th Report. 2008.
12. Raviglione M. XDR-TB: entering the postantibiotic era? Int J Tuberc Lung Dis 2006; 10:1185-1187.
13. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-1580.
14. Harries AD, Nyirenda TE, Godfrey-Faussett P, Salaniponi FM. Defining and assessing the maximum number of visits patients should make to a health facility to obtain a diagnosis of pulmonary tuberculosis. Int J Tuberc Lung Dis 2003; 7:953-958.
15. Millen SJ, Uys PW, Hargrove J, et al. The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PLoS ONE 2008; 3:e1933. An excellent review of the everyday difficulties faced and delays encountered when diagnosing tuberculosis in the developing world.
16. Cunningham J, Perkins M. Diagnostics for tuberculosis; global demand and market potential. Geneva: World Health Organisation; 2006.
17. Phillips M, Cataneo RN, Condos R, et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb) 2007; 87:44-52.
18. Butcher PD. Microarrays for Mycobacterium tuberculosis. Tuberculosis (Edinb) 2004; 84:131-137.
19. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006; 368:1012-1021.
20. Hasegawa M, Koyama E, Uchino U, et al. Evaluation of rapid identification method for Mycobacterium tuberculosis complex using the immunochromatographic slide test kit. Kansenshogaku Zasshi 2003; 77:110-115.
21. Steingart KR, Henry M, Laal S, et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 2007; 4:e202. An excellent systematic review highlighting the limited evidence for serological antibody detection of pulmonary tuberculosis.
22. World Health Organisation. Guidelines for the prevention of tuberculosis in healthcare facilities in resource-limited settings. Geneva: World Health Organisation; 1999.
23. Centers for Disease Control and Prevention and National Institutes of Health. Biosafety in microbiological and biomedical laboratories. 2007 (Fifth Edition). A helpful resource providing information on biosafety requirements necessary for tuberculosis diagnosis.
24. Kim SJ, Lee SH, Kim IS, et al. Risk of occupational tuberculosis in National Tuberculosis Programme laboratories in Korea. Int J Tuberc Lung Dis 2007; 11:138-142. An elegant analysis comparing the incidence of tuberculosis infection in laboratory staff working with clearly defined duties in microscopy, culture inoculation or DST involving strain manipulation. Significantly higher incidence of tuberculosis infection was observed in the latter group.
25. Kvach JT, Munguia G, Strand SH. Staining tissue-derived Mycobacterium leprae with fluorescein diacetate and ethidium bromide. Int J Lepr Other Mycobact Dis 1984; 52:176-182.
26. Harada S, Numata N. Application of FDA/EB staining for the detection of viable or nonviable mycobacteria in clinical specimens. Kekkaku 1992; 67:113-117.
27. Hamid Salim A, Aung KJ, Hossain MA, Van Deun A. Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Int J Tuberc Lung Dis 2006; 10:1248-1254.
28. Canetti G, Froman S, Grosset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29:565-578.
29. Mitchison DA. Drug resistance in tuberculosis. Eur Respir J 2005; 25:376-379.
30. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41:21-43.
31. Wanger A, Mills K. Etest for susceptibility testing of Mycobacterium tuberculosis and Mycobacterium avium-intracellulare. Diagn Microbiol Infect Dis 1994; 19:179-181.
32. Birinci A, Coban AY, Ekinci B, Durupinar B. Comparison of the proportion method with mycobacteria growth indicator tube and E-test for susceptibility testing of Mycobacterium tuberculosis. Mem Inst Oswaldo Cruz 2002; 97:351-352.
33. Muralidhar S, Srivastava L. Evaluation of three methods to determine the antimicrobial susceptibility of Mycobacterium tuberculosis. Indian J Med Res 2004; 120:463-467.
34. Wanger A, Mills K. Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest. J Clin Microbiol 1996; 34:1672-1676.
35. Esteban J, Ortiz A, Jimenez MS. Usefulness of E-test strips for testing susceptibility of Mycobacterium tuberculosis complex strains. Eur J Clin Microbiol Infect Dis 2005; 24:856-857.
36. Baylan O, Kisa O, Albay A, Doganci L. Evaluation of a new automated, rapid, colorimetric culture system using solid medium for laboratory diagnosis of tuberculosis and determination of antituberculosis drug susceptibility. Int J Tuberc Lung Dis 2004; 8:772-777.
37. Runyon EH. Identification of mycobacterial pathogens utilizing colony characteristics. Am J Clin Pathol 1970; 54:578-586.
38. Welch DF, Guruswamy AP, Sides SJ, et al. Timely culture for mycobacteria which utilizes a microcolony method. J Clin Microbiol 1993; 31:2178-2184.
39. Mejia GI, Castrillon L, Trujillo H, Robledo JA. Microcolony detection in 7H11 thin layer culture is an alternative for rapid diagnosis of Mycobacterium tuberculosis infection. Int J Tuberc Lung Dis 1999; 3:138-142.
40. Robledo JA, Mejia GI, Morcillo N, et al. Evaluation of a rapid culture method for tuberculosis diagnosis: a Latin American multicenter study. Int J Tuberc Lung Dis 2006; 10:613-619.
41. Cummings DM, Ristroph D, Camargo EE, et al. Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med 1975; 16:1189-1191.
42. Roberts GD, Goodman NL, Heifets L, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol 1983; 18:689-696.
43. Siddiqi SH, Hawkins JE, Laszlo A. Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods. J Clin Microbiol 1985; 22:919-923.
44. Siddiqi SH, Libonati JP, Middlebrook G. Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 1981; 13:908-912. Millen SJ, Uys PW, Hargrove J, et al. The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PLoS ONE 2008; 3:e1933. An excellent review of the everyday difficulties faced and delays encountered when diagnosing tuberculosis in the developing world.
45. Pfyffer GE, Bonato DA, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37:3179-3186.
46. Hanna BA, Ebrahimzadeh A, Elliott LB, et al. Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. J Clin Microbiol 1999; 37:748-752.
47. Cambau E, Wichlacz C, Truffot-Pernot C, Jarlier V. Evaluation of the new MB redox system for detection of growth of mycobacteria. J Clin Microbiol 1999; 37:2013-2015.
48. Rohner P, Ninet B, Metral C, et al. Evaluation of the MB/BacT system and comparison to the BACTEC 460 system and solid media for isolation of mycobacteria from clinical specimens. J Clin Microbiol 1997; 35:3127-3131.
49. Woods GL, Fish G, Plaunt M, Murphy T. Clinical evaluation of difco ESP culture system II for growth and detection of mycobacteria. J Clin Microbiol 1997; 35:121-124.
50. Garrigo M, Aragon LM, Alcaide F, et al. Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2007; 45:1766-1770. A useful comparison of the Bactec MGIT960 and its predecessor the Bactec 460 on 82 M. tuberculosis strains. All discrepant results were resolved by molecular characterisation and MIC determination.
51. Ruiz P, Zerolo FJ, Casal MJ. Comparison of susceptibility testing of Myco-bacterium tuberculosis using the ESP culture system II with that using the BACTEC method. J Clin Microbiol 2000; 38:4663-4664.
52. Barreto AM, Araujo JB, de Melo Medeiros RF, de Souza Caldas PC. Evaluation of indirect susceptibility testing of Mycobacterium tuberculosis to the first- and second-line, and alternative drugs by the newer MB/BacT system. Mem Inst Oswaldo Cruz 2003; 98:827-830.
53. Ardito F, Posteraro B, Sanguinetti M, et al. Evaluation of BACTEC Myco-bacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2001; 39:4440-4444.
54. Somoskovi A, Kodmon C, Lantos A, et al. Comparison of recoveries of mycobacterium tuberculosis using the automated BACTEC MGIT 960 system, the BACTEC 460 TB system, and Lowenstein-Jensen medium. J Clin Microbiol 2000; 38:2395-2397.
55. Bemer P, Palicova F, Rusch-Gerdes S, et al. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40:150-154.
56. Kontos F, Maniati M, Costopoulos C, et al. Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study. J Microbiol Methods 2004; 56:291-294.
57. Kruuner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of firstand second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44:811-818.
58. Rusch-Gerdes S, Pfyffer GE, Casal M, et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Myco-bacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44:688-692.
59. Scarparo C, Ricordi P, Ruggiero G, Piccoli P. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol 2004; 42:1109-1114.
60. Tortoli E, Benedetti M, Fontanelli A, Simonetti MT. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radio-metric BACTEC 460TB method and the agar plate method of proportion. J Clin Microbiol 2002; 40:607-610.
61. World Health Organisation. Strategic TB Advisory Group (STAG-TB); Report on conclusions and recommendations. Geneva: World Health Organisation; 2007. Recent recommendations from the Strategic Tuberculosis Advisory Group (STAG) and revision of the MDR-TB global plan.
62. Caviedes L, Lee TS, Gilman RH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. J Clin Microbiol 2000; 38:1203-1208.
63. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539-1550.
64. Arias M, Mello FC, Pavon A, et al. Clinical evaluation of the microscopic-observation drug-susceptibility assay for detection of tuberculosis. Clin Infect Dis 2007; 44:674-680.
65. Ejigu GS, Woldeamanuel Y, Shah NS, et al. Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB. Int J Tuberc Lung Dis 2008; 12:332-337.
66. Shiferaw G, Woldeamanuel Y, Gebeyehu M, et al. Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2007; 45:1093-1097.
67. Tovar M, Siedner MJ, Gilman RH, et al. Improved diagnosis of pleural tuberculosis using the microscopic-observation drug-susceptibility technique. Clin Infect Dis 2008; 46:909-912.
68. Caws M, Dang TM, Torok E, et al. Evaluation of the MODS culture technique for the diagnosis of tuberculous meningitis. PLoS ONE 2007; 2:e1173. MODS sensitive for diagnosis of tuberculous meningitis.
69. Grandjean L, Martin L, Gilman RH, et al. Tuberculosis diagnosis and multidrug resistance testing by direct sputum culture in selective broth without decontamination or centrifugation. J Clin Microbiol 2008; 46:2339-2344. Simplification of MODS obviating the need for centrifugation and decontamination steps by use of selective media. A step closer to MODS use as a point of care test.
70. Adjers-Koskela K, Katila ML. Susceptibility testing with the manual myco-bacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. J Clin Microbiol 2003; 41:1235-1239.
71. Palomino JC, Martin A, Portaels F. Rapid drug resistance detection in Mycobacterium tuberculosis: a review of colourimetric methods. Clin Microbiol Infect 2007; 13:754-762.
72. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997; 41:1004-1009.
73. Martin A, Camacho M, Portaels F, Palomino JC. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003; 47:3616-3619.
74. Yajko DM, Madej JJ, Lancaster MV, et al. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol 1995; 33:2324-2327.
75. Morcillo N, Di Giulio B, Testani B, et al. A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents. Int J Tuberc Lung Dis 2004; 8:253-259.
76. Musa HR, Ambroggi M, Souto A, Angeby KA. Drug susceptibility testing of Mycobacterium tuberculosis by a nitrate reductase assay applied directly on microscopy-positive sputum samples. J Clin Microbiol 2005; 43:3159-3161.
77. Angeby KA, Klintz L, Hoffner SE. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol 2002; 40:553-555.
78. Solis LA, Shin SS, Han LL, et al. Validation of a rapid method for detection of M. tuberculosis resistance to isoniazid and rifampin in Lima, Peru. Int J Tuberc Lung Dis 2005; 9:760-764.
79. Martin A, Panaiotov S, Portaels F, et al. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2008; 62:56-64. A systematic review of the use of the nitrate reductase assay for diagnosis of MDR tuberculosis. A sensitive method allowing diagnosis and indirect drug susceptibility testing by direct vision. More evidence required for direct drug susceptibility testing.
80. Wilson SM, al-Suwaidi Z, McNerney R, et al. Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Myco-bacterium tuberculosis. Nat Med 1997; 3:465-468.
81. Eltringham IJ, Wilson SM, Drobniewski FA. Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis. J Clin Microbiol 1999; 37:3528-3532.
82. Gali N, Dominguez J, Blanco S, et al. Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance. J Clin Microbiol 2006; 44:201-205.
83. Gali N, Dominguez J, Blanco S, et al. Utility of an in-house mycobacteriophage-based assay for rapid detection of rifampin resistance in Mycobacterium tuberculosis clinical isolates. J Clin Microbiol 2003; 41:2647-2649.
84. McNerney R, Kiepiela P, Bishop KS, et al. Rapid screening of Mycobacterium tuberculosis for susceptibility to rifampicin and streptomycin. Int J Tuberc Lung Dis 2000; 4:69-75.
85. Biswas D, Deb A, Gupta P, et al. Evaluation of the usefulness of phage amplification technology in the diagnosis of patients with paucibacillary tuberculosis. Indian J Med Microbiol 2008; 26:75-78.
86. Mbulo GM, Kambashi BS, Kinkese J, et al. Comparison of two bacteriophage tests and nucleic acid amplification for the diagnosis of pulmonary tuberculosis in sub-Saharan Africa. Int J Tuberc Lung Dis 2004; 8:1342-1347.
87. World Health Organisation. Anti-tuberculosis drug resistance in the world; third global report. Geneva: World Health Organisation; 2004.
88. Kapur V, Li LL, Iordanescu S, et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32:1095-1098.
89. Nikolayevsky V, Brown T, Balabanova Y, et al. Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J Clin Microbiol 2004; 42:4498-4502.
90. Drobniewski FA, Hoffner S, Rusch-Gerdes S, et al. Recommended standards for modern tuberculosis laboratory services in Europe. Eur Respir J 2006; 28:903-909.
91. Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 2000; 28:e63.
92. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Myco-bacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45:2635-2640.
93. Boehme CC, Nabeta P, Henostroza G, et al. Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J Clin Microbiol 2007; 45:1936-1940. First field evaluation of LAMP, highlighting potential obstacles common to many diagnostics.
94. Genotype MTBDRplus. In: Nehren, Germany: Hain Lifescience, GmbH; 2007. Comparison of the MTBDRplus with the earlier version.
95. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45:2635-2640.
96. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177:787-792. Excellent evaluation of the Hain Genotype MTBDR test demonstrating reliable determination of MDRTB and sensitive diagnosis of tuberculosis in smear-positive sputum samples. More work required evaluating smear-negative, culture-positive samples.
97. Tortoli E, Marcelli F. Use of the INNO LiPA Rif. TB for detection of Myco-bacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur J Clin Microbiol Infect Dis 2007; 26:51-55.
98. World Health Organisation. Guidelines for surveillance of drug resistance in tuberculosis. WHO Geneva/IUATLD Paris. International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 1998; 2:72-89.
99. Butler WR, Ahearn DG, Kilburn JO. High-performance liquid chromatography of mycolic acids as a tool in the identification of Corynebacterium, Nocardia, Rhodococcus, and Mycobacterium species. J Clin Microbiol 1986; 23:182-185.
100. Qureshi N, Takayama K, Jordi HC, Schnoes HK. Characterization of the purified components of a new homologous series of alpha-mycolic acids from Mycobacterium tuberculosis H37Ra. J Biol Chem 1978; 253:5411-5417.
101. Steck PA, Schwartz BA, Rosendahl MS, Gray GR. Mycolic acids. A reinvestigation. J Biol Chem 1978; 253:5625-5629.
102. Garza-Gonzalez E, Guerrero-Olazaran M, Tijerina-Menchaca R, Viader-Salvado JM. Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis. J Clin Microbiol 1997; 35:1287-1289.
103. Parrish N, Osterhout G, Dionne K, et al. Rapid, standardized method for determination of Mycobacterium tuberculosis drug susceptibility by use of mycolic acid analysis. J Clin Microbiol 2007; 45:3915-3920. Evaluation of mycolic acid chromatography for the diagnosis of drug resistant tuberculosis - a promising new diagnostic avenue if HPLC can be translated into a low-cost, field-friendly format.
104. Department of Health. Tuberculosis prevention and treatment: a toolkit for planning, commissioning and delivering high-quality services in England. London: Department of Health; 2007.
105. National Institute of Clinical Excellence (NICE). Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2006. Genotype MTBDRplus. In: Nehren, Germany: Hain Lifescience, GmbH; 2007. Comparison of the MTBDRplus with the earlier version.